Site searchIR News
- 2023.8.10
- 2023.5.12Financial Results for the Fiscal Year ended March 31, 2023 [Japanese GAAP] (non-consolidated)（567KB）
- 2023.5.2BrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications（173KB）
- 2022.11.10BrightPath to Update the Pre-clinical Data of BP1210 and BP1212 at SITC 2022（218KB）
- 2022.11.10BrightPath to Update the Pre-clinical Data of iPS-NKT at SITC 2022（216KB）
- 2022.11.10BrightPath to Update the Pre-clinical Data of BP1202 at SITC 2022（324KB）
- 2022.11.1BrightPath Exercised the Option to Obtain Exclusive Development, Manufacturing and Marketing License for iPS-NKT from RIKEN（131KB）
- 2022.10.5BrightPath to Update the Pre-clinical Data of iPS-NKT, BP1202 and BP1212 at SITC 2022（321KB）
- 2022.5.12Announcement of the early termination of a phase II clinical trial of the cancer peptide vaccine GRN-1201 in the United States and Top-line data （254KB）
- 2022.5.12 Financial Results for the Fiscal Year ended March 31, 2022 [Japanese GAAP]（423KB）
- 2022.5.9Phase I clinical trial initiated for HER2-targeted CAR-T cell therapy BP2301（225 KB）
- 2022.4.13BrightPath Presents Preclinical Data on a CD73 antagonist antibody at AACR 2022（214KB）
- 2022.4.13BrightPath Presents New Data on Personalized Neoantigen Vaccine at AACR 2022（268KB）
- 2022.4.11BrightPath Presents New Data on Personalized Neoantigen Vaccine at AACR 2022（313KB）
- 2022.4.11BrightPath Presents New Data on Preclinical Data on BP2301(HER2 CAR-T) at AACR 2022（288KB）
- 2021.11.12BrightPath to Present Updates on the Pre-clinical Data of BP1210 at SITC 2021（214KB）
- 2021.9.24BrightPath's abstract on a CD73 antagonist antibody wins Best Poster Award at ESMO 2021（277KB）
- 2021.5.13 Financial Results for the Fiscal Year ended March 31, 2021 [Japanese GAAP]（445KB）
- 2019.12.24BrightPath Concludes Agreements with Osaka University, BIKEN Foundation and Teikyo University for Development of TLR9 Agonist Lipid-Nucleic Acid as Immuno-stimulator（227KB）
- 2019.8.19Shinshu University and BrightPath Conclude Joint R&D Agreement for CAR-T Cell Therapy for Solid Tumors（1456KB）
- 2019.8.9Announcement on the Results of a Phase I Clinical Trial in Melanoma for Cancer Peptide Vaccine GRN-1201（185KB）
- 2019.5.10 Financial Results for the Fiscal Year ended March 31, 2019 [Japanese GAAP]（347KB）
- 2019.3.15Announcement on the Waiver of Claims for a Subsidiary, Shift to Non-consolidated Settlement of Accounts, and Disclosure of Forecast for Non-consolidated Financial Results（112KB）
- 2018.12.19University of Tokyo and BrightPath Conclude Collaborative Research Agreement for Fully Personalized Cancer Immunotherapy（167KB）
- 2018.11.9 Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（162KB）
- 2018.10.12Announcement on Dissolution of a Subsidiary（324KB）
- 2018.8.10 Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（143KB）
- 2018.5.17Announcement on the Results of the Phase III Clinical Trial for Cancer Peptide Vaccine ITK-1 in Patients in Japan with Prostate Cancer（276KB）
- 2018.5.15 Financial Results for the Fiscal Year ended March 31, 2018 [Japanese GAAP] (Consolidated)（505KB）
- 2018.3.29Collaborative research agreement concluded with RIKEN on iPS cell-derived NKT cell therapy（801KB）
- 2018.2.14 Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（395KB）
- 2018.1.25BrightPath concludes agreement to develop personalized cancer vaccine（322KB）
- 2018.1.15Mie University and BrightPath Launch New Program for Neoantigen-based Personalized Cancer Immunotherapy（187KB）
- 2017.11.17Patent Issued in Japan on Method for Reconstructing Immune Function Using Pluripotent Stem Cells（176KB）
- 2017.11.10 Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（935KB）
- 2017.10.27Collaborative Research on Fully-personalized Cancer Neoantigen Vaccine（583KB）
- 2017.8.14 Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（805KB）
- 2017.7.24Patent for rejuvenated antigen-specific T lymphocytes using iPS cells（367KB）
- 2017.7.20Decision to grant patent for CTL inducer composition by Canadian Intellectual Property Office（633KB）
- 2017.5.15Decision to Grant a Patent Related to Antigenic Peptides Derived from the T790M Point Mutation of Epidermal Growth Factor Receptor（93KB）
- 2017.5.12 Financial Results for the Fiscal Year ended March 31, 2017 [Japanese GAAP] (Consolidated)（171KB）
- 2017.5.12Announcement on the Change of the Corporate Name and Partial Amendment to the Articles of Incorporation（66KB）
- 2017.2.10 Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (Consolidated)（183KB）
- 2017.1.27Notice of the initiation of a phase II clinical trial of GRN-1201 with the concomitant use of an immune checkpoint antibody against NSCLC in the U.S.（90KB）
- 2016.12.9IR Information on the Initiation of Neoantigen (Genetic Variant Antigen) Peptide Vaccine Development（1393KB）
- 2016.11.21Announcement of the Acceptance of the Third Party Allocation of New Shares by Advanced Immunotherapy, Co., Ltd. (Acquisition of the Ownership)（623KB）
- 2016.11.19 Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（184KB）
- 2016.8.15 Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2017 [Japanese GAAP] (non-consolidated)（178KB）
- 2016.8.9Announcement of Joint Research and Development with Kanagawa Cancer Center（145KB）
- 2016.7.25Announcement Concerning Development of Immunoassay Procedures Outsourced to GreenPeptide（125KB）
- 2016.5.13 Financial Results for the Fiscal Year ended March 31, 2016 [Japanese GAAP]（167KB）
- 2016.5.2Completion of Patient Enrollment in Japanese Phase III Clinical Study on GreenPeptide's Lead Product Candidate ITK-1（86 KB）
- 2016.2.12 Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2016 [Japanese GAAP] (non-consolidated)（158KB）
Adobe Reader is required to view these PDF files